ProKidney Corp. (PROK) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. ProKidney Corp. is a late-clinical-stage biotechnology company developing rilparencel, an autologous cell therapy for advanced chronic kidney disease (CKD) and type 2 diabetes. The company is currently conducting the Phase 3 PROACT 1 clinical trial. The company completed a domestication from the Cayman Islands to Delaware effective July 1, 2025, and operates as a single segment. It is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Value (in thousands) |
|---|---|
| Revenue | $376 |
| Net Loss (Class A Stockholders) | $(48,459) |
| Net Loss Per Share (Basic & Diluted) | $(0.29) |
| Operating Expenses | $93,682 |
| Research & Development (R&D) | $69,937 |
| General & Administrative (G&A) | $23,745 |
| Cash & Cash Equivalents | $74,868 |
| Marketable Securities | $106,696 |
| Total Liquidity | $181,564 |
| Accumulated Deficit | $(1,318,294) |
| Net Cash Used in Operating Activities | $(82,058) |
Material Changes vs. Prior Period
- Revenue: Decreased by $75,000 (17%) compared to the six months ended June 30, 2025, due to lower leasing revenue from subletting facility space.
- R&D Expenses: Increased by $16.8 million (32%) year-over-year. This was driven primarily by a $14.6 million increase in clinical study costs and manufacturing materials for the Phase 3 PROACT 1 trial, alongside increased compensation costs.
- G&A Expenses: Decreased by $4.7 million (16%) year-over-year. Reductions were attributed to lower equity-based compensation (completion of legacy profit interest vesting), reduced professional fees, and lower severance payments.
- Interest Income: Decreased by $3.4 million year-over-year due to lower average investment balances and interest rates.
- Net Loss: Net loss attributable to Class A stockholders increased by $15.2 million to $48.5 million.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management explicitly states that existing cash and marketable securities ($181.6 million) are not sufficient to fund operations for the 12 months following the filing date (August 10, 2026). This raises substantial doubt about the company's ability to continue as a going concern.
- Clinical Trial Status: Enrollment for the accelerated approval efficacy analysis (approx. 320 patients) in the PROACT 1 trial is complete. Topline data for the surrogate endpoint (eGFR slope) is anticipated in Q2 2027, with confirmatory data expected in H2 2029.
- Capital Needs: The company expects to require substantial additional funding through equity offerings, debt, or collaborations to continue operations. Failure to secure funding could force delays or elimination of R&D programs.
- Equity Transactions: During the period, a significant exchange of Class B common stock for Class A common stock occurred (approx. 63.4 million shares), reducing the redeemable noncontrolling interest.
Investor Verification Checklist
- Liquidity Runway: Verify the specific timeline for the next capital raise given the "substantial doubt" disclosure regarding 12-month solvency.
- PROACT 1 Trial Costs: Confirm the burn rate associated with the Phase 3 trial and whether the current cash balance can sustain the trial through the anticipated Q2 2027 data readout.
- Noncontrolling Interest: Review the terms of the Exchange Agreement and the remaining 32% noncontrolling interest in PK Holdings, which impacts the net loss attributable to public shareholders.
- Revenue Model: Note that revenue is currently derived solely from facility leasing, not product sales, and no product revenue is expected in the near future.
- Equity Dilution: Assess the potential dilution from the $200 million "at-the-market" sales agreement and future fundraising requirements.